Sino-US firm Analytical BioSciences Limited has entered into an asset purchase agreement with Gilead (NASDAQ: GILD), granting the US firm global rights to Analytical’s multiple pre-clinical anti-tumor candidate drug assets. The financial details of the upfront and milestone payments remain undisclosed, and Gilead will also grant Analytical priority purchase rights to one of the assets for mainland China.
Innovative Cancer Immunotherapy Method Involved in the Deal
The agreement encompasses a novel method pioneered by Analytical in the field of cancer immunotherapy. This method involves inducing the formation of tertiary lymphoid structures (TLS) by reprogramming cancer-associated fibroblasts (CAFs) within the tumor microenvironment. This approach represents a significant advancement in the development of immunotherapies that could potentially enhance the body’s immune response to cancer.
Pre-Clinical Success and Potential for Combination Therapies
In multiple preclinical models, the molecules developed using this method have demonstrated significant potential to overcome resistance to immune checkpoint inhibitors. Furthermore, they have shown effectiveness when used in combination with various treatment strategies, indicating their versatility and potential impact on improving cancer treatment outcomes.-Fineline Info & Tech
